+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hepatic Encephalopathy Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 to 2031

  • PDF Icon

    Report

  • 118 Pages
  • January 2023
  • Region: Global
  • Acute Market Reports
  • ID: 5767141
Description Jump to:
Hepatic Encephalopathy Therapeutics Market is projected to expandat a CAGR Of 6.5% between 2023 and 2031. As per the citing of the National Organization for Rare Diseases (NORD) 2016 report, hepatic encephalopathy is described as a brain disorder in patients previously suffering from chronic liver ailments such as liver cirrhosis, hepatitis, and acute liver failure. If effectively diagnosed, hepatic encephalopathy occurs in almost two-thirds of the patients suffering from liver cirrhosis. Hepatic encephalopathy is categorized into 3 types Type A (acute liver failure), Type B (portal systemic bypass without liver disease), and Type C (liver cirrhosis). The exact disease etiology is unknown but the disease is triggered by the accumulation of toxins in the bloodstream as the diseased liver fails to neutralize the toxins. The clinical manifestation associated with hepatic encephalopathy is confusion, anxiety, lethargy, seizures, confused speech, personality changes, and poor body movements. The key factors driving the hepatic encephalopathy therapeutics market are the rising prevalence of liver disorders, lack of nutrients in daily food intake, and increasing public health awareness resulting in early diagnosis and treatment.

The diagnosis of hepatic encephalopathy includes blood tests, liver function tests, detection of serum ammonia levels, and an encephalogram of the brain to measure the electrical activity of the brain. There are numerous therapeutic approaches to manage the severity of hepatic encephalopathy, but the reduction of plasma ammonia is the most preferred strategy. Lactulose is the first line of treatment as it changes the acidity of the stool to reduce the production of ammonia by killing intestinal bacteria. Probiotics and thiamine are useful in the treatment of hepatic encephalopathy by increasing the expulsion of ammonia genic bacteria by causing the bowel to get fermented by colonic bacteria to produce lactic and acetic acid. In 2010 the USFDA approved Rifaximin for the treatment of hepatic encephalopathy by acting on the microorganisms in the intestinal tract producing ammonia.

Key players identified for the Hepatic Encephalopathy market include:

Mallinckrodt Pharmaceuticals, Salix Pharmaceuticals, GlaxoSmithKline plc., Pfizer Inc., ASKA Pharmaceutical Co., Ltd., Bausch Health, Johnson & Johnson Services, Inc., Janssen Global Services, Takeda Pharmaceutical Company Limited, Merck & Co., Inc., and others.

Historical & Forecast Period

This study report represents an analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends, and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. A key data point that enables the estimation of the Hepatic Encephalopathy Therapeutics market is as follows:
  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Several end users and consumption volume, price, and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Hepatic Encephalopathy Therapeutics market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approaches for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

  • Antibiotics
  • Laxatives
  • L-ornithine
  • L-aspartate

Diagnosis

  • Blood Tests
  • CT Scan
  • Liver Functioning Tests

Route of Administration

  • Oral
  • Injectable
  • Intravenous
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of the Hepatic Encephalopathy Therapeutics market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Hepatic Encephalopathy Therapeutics market?
  • Which is the largest regional market for the Hepatic Encephalopathy Therapeutics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving the Hepatic Encephalopathy Therapeutics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Hepatic Encephalopathy Therapeutics market worldwide?


This product will be delivered within 2 business days.

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Hepatic Encephalopathy Therapeutics Market
2.2. Global Hepatic Encephalopathy Therapeutics Market, By Drug Class, 2022 (US$ Million)
2.3. Global Hepatic Encephalopathy Therapeutics Market, By Diagnosis, 2022 (US$ Million)
2.4. Global Hepatic Encephalopathy Therapeutics Market, By Route of Administration, 2022 (US$ Million)
2.5. Global Hepatic Encephalopathy Therapeutics Market, By Distribution Channel, 2022 (US$ Million)
2.6. Global Hepatic Encephalopathy Therapeutics Market, By Geography, 2022 (US$ Million)
2.7. Attractive Investment Proposition by Geography, 2022

3. Hepatic Encephalopathy Therapeutics Market: Competitive Analysis
3.1. Market Positioning of Key Hepatic Encephalopathy Therapeutics Market Vendors
3.2. Strategies Adopted by Hepatic Encephalopathy Therapeutics Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2022 Versus 2031

4. Hepatic Encephalopathy Therapeutics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Hepatic Encephalopathy Therapeutics Market Value, 2021 - 2031, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis

5. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2022 Versus 2031
5.3. Market Segmentation
5.3.1. Antibiotics
5.3.2. Laxatives
5.3.3. L-ornithine
5.3.4. L-aspartate

6. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2022 Versus 2031
6.3. Market Segmentation
6.3.1. Blood Tests
6.3.2. CT Scan
6.3.3. Liver Functioning Tests

7. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2022 Versus 2031
7.3. Market Segmentation
7.3.1. Oral
7.3.2. Injectable
7.3.3. Intravenous
7.3.4. Others

8. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
8.1. Market Overview
8.2. Growth & Revenue Analysis: 2022 Versus 2031
8.3. Market Segmentation
8.3.1. Hospital Pharmacy
8.3.2. Online Pharmacy
8.3.3. Retail Pharmacy

9. North America Hepatic Encephalopathy Therapeutics Market, 2021-2031, USD (Million)
9.1. Market Overview
9.2. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
9.3. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
9.4. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
9.5. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
9.6.Hepatic Encephalopathy Therapeutics Market: By Region, 2021-2031, USD (Million)
9.6.1.North America
9.6.1.1. U.S.
9.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
9.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
9.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
9.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
9.6.1.2. Canada
9.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
9.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
9.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
9.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
9.6.1.3. Rest of North America
9.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
9.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
9.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
9.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)

10. UK and European Union Hepatic Encephalopathy Therapeutics Market, 2021-2031, USD (Million)
10.1. Market Overview
10.2. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
10.3. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
10.4. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
10.5. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
10.6.Hepatic Encephalopathy Therapeutics Market: By Region, 2021-2031, USD (Million)
10.6.1.UK and European Union
10.6.1.1. UK
10.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
10.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
10.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
10.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
10.6.1.2. Germany
10.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
10.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
10.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
10.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
10.6.1.3. Spain
10.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
10.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
10.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
10.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
10.6.1.4. Italy
10.6.1.4.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
10.6.1.4.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
10.6.1.4.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
10.6.1.4.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
10.6.1.5. France
10.6.1.5.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
10.6.1.5.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
10.6.1.5.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
10.6.1.5.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
10.6.1.6. Rest of Europe
10.6.1.6.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
10.6.1.6.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
10.6.1.6.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
10.6.1.6.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)

11. Asia Pacific Hepatic Encephalopathy Therapeutics Market, 2021-2031, USD (Million)
11.1. Market Overview
11.2. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
11.3. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
11.4. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
11.5. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
11.6.Hepatic Encephalopathy Therapeutics Market: By Region, 2021-2031, USD (Million)
11.6.1.Asia Pacific
11.6.1.1. China
11.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
11.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
11.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
11.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
11.6.1.2. Japan
11.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
11.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
11.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
11.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
11.6.1.3. India
11.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
11.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
11.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
11.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
11.6.1.4. Australia
11.6.1.4.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
11.6.1.4.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
11.6.1.4.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
11.6.1.4.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
11.6.1.5. South Korea
11.6.1.5.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
11.6.1.5.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
11.6.1.5.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
11.6.1.5.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
11.6.1.6. Rest of Asia Pacific
11.6.1.6.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
11.6.1.6.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
11.6.1.6.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
11.6.1.6.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)

12. Latin America Hepatic Encephalopathy Therapeutics Market, 2021-2031, USD (Million)
12.1. Market Overview
12.2. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
12.3. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
12.4. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
12.5. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
12.6.Hepatic Encephalopathy Therapeutics Market: By Region, 2021-2031, USD (Million)
12.6.1.Latin America
12.6.1.1. Brazil
12.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
12.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
12.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
12.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
12.6.1.2. Mexico
12.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
12.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
12.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
12.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
12.6.1.3. Rest of Latin America
12.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
12.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
12.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
12.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)

13. Middle East and Africa Hepatic Encephalopathy Therapeutics Market, 2021-2031, USD (Million)
13.1. Market Overview
13.2. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
13.3. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
13.4. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
13.5. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
13.6.Hepatic Encephalopathy Therapeutics Market: By Region, 2021-2031, USD (Million)
13.6.1.Middle East and Africa
13.6.1.1. GCC
13.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
13.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
13.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
13.6.1.1.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
13.6.1.2. Africa
13.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
13.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
13.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
13.6.1.2.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)
13.6.1.3. Rest of Middle East and Africa
13.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Drug Class, 2021-2031, USD (Million)
13.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Diagnosis, 2021-2031, USD (Million)
13.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Route of Administration, 2021-2031, USD (Million)
13.6.1.3.1. Hepatic Encephalopathy Therapeutics Market: By Distribution Channel, 2021-2031, USD (Million)

14. Company Profile
14.1. Mallinckrodt Pharmaceuticals
14.1.1. Company Overview
14.1.2. Financial Performance
14.1.3. Product Portfolio
14.1.4. Strategic Initiatives
14.2. Salix Pharmaceuticals
14.2.1. Company Overview
14.2.2. Financial Performance
14.2.3. Product Portfolio
14.2.4. Strategic Initiatives
14.3. GlaxoSmithKline plc.
14.3.1. Company Overview
14.3.2. Financial Performance
14.3.3. Product Portfolio
14.3.4. Strategic Initiatives
14.4. Pfizer Inc.
14.4.1. Company Overview
14.4.2. Financial Performance
14.4.3. Product Portfolio
14.4.4. Strategic Initiatives
14.5. ASKA Pharmaceutical Co., Ltd.
14.5.1. Company Overview
14.5.2. Financial Performance
14.5.3. Product Portfolio
14.5.4. Strategic Initiatives
14.6. Bausch Health
14.6.1. Company Overview
14.6.2. Financial Performance
14.6.3. Product Portfolio
14.6.4. Strategic Initiatives
14.7. Johnson & Johnson Services, Inc.
14.7.1. Company Overview
14.7.2. Financial Performance
14.7.3. Product Portfolio
14.7.4. Strategic Initiatives
14.8. Janssen Global Services
14.8.1. Company Overview
14.8.2. Financial Performance
14.8.3. Product Portfolio
14.8.4. Strategic Initiatives
14.9. Takeda Pharmaceutical Company Limited, Merck & Co., Inc.
14.9.1. Company Overview
14.9.2. Financial Performance
14.9.3. Product Portfolio
14.9.4. Strategic Initiatives
14.10. Others
14.10.1. Company Overview
14.10.2. Financial Performance
14.10.3. Product Portfolio
14.10.4. Strategic Initiatives

List of Figures
Figure 1 Global Hepatic Encephalopathy Therapeutics Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Hepatic Encephalopathy Therapeutics Market: Quality Assurance
Figure 5 Global Hepatic Encephalopathy Therapeutics Market, By Drug Class, 2022
Figure 6 Global Hepatic Encephalopathy Therapeutics Market, By Diagnosis, 2022
Figure 7 Global Hepatic Encephalopathy Therapeutics Market, By Route of Administration, 2022
Figure 8 Global Hepatic Encephalopathy Therapeutics Market, By Distribution Channel, 2022
Figure 9 Global Hepatic Encephalopathy Therapeutics Market, By Geography, 2022
Figure 10 Market Geographical Opportunity Matrix - Global Hepatic Encephalopathy Therapeutics Market, 2022
Figure 11 Market Positioning of Key Hepatic Encephalopathy Therapeutics Market Players, 2022
Figure 12 Global Hepatic Encephalopathy Therapeutics Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
Figure 13 Global Hepatic Encephalopathy Therapeutics Market, By Drug Class, 2022 Vs 2031, %
Figure 14 Global Hepatic Encephalopathy Therapeutics Market, By Diagnosis, 2022 Vs 2031, %
Figure 15 Global Hepatic Encephalopathy Therapeutics Market, By Route of Administration, 2022 Vs 2031, %
Figure 16 Global Hepatic Encephalopathy Therapeutics Market, By Distribution Channel, 2022 Vs 2031, %
Figure 17 U.S. Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 18 Canada Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 19 Rest of North America Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 20 UK Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 21 Germany Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 22 Spain Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 23 Italy Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 24 France Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 25 Rest of Europe Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 26 China Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 27 Japan Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 28 India Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 29 Australia Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 30 South Korea Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 31 Rest of Asia Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 32 Brazil Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 33 Mexico Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 34 Rest of Latin America Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 35 GCC Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 36 Africa Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031
Figure 37 Rest of Middle East and Africa Hepatic Encephalopathy Therapeutics Market (US$ Million), 2021 - 2031

List of Figures
Table 1 Global Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 2 Global Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 3 Global Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 4 Global Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 5 North America Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 6 North America Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 7 North America Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 8 North America Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 9 U.S. Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 10 U.S. Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 11 U.S. Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 12 U.S. Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 13 Canada Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 14 Canada Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 15 Canada Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 16 Canada Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 17 Rest of North America Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 18 Rest of North America Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 19 Rest of North America Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 20 Rest of North America Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 21 UK and European Union Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 22 UK and European Union Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 23 UK and European Union Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 24 UK and European Union Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 25 UK Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 26 UK Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 27 UK Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 28 UK Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 29 Germany Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 30 Germany Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 31 Germany Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 32 Germany Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 33 Spain Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 34 Spain Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 35 Spain Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 36 Spain Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 37 Italy Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 38 Italy Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 39 Italy Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 40 Italy Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 41 France Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 42 France Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 43 France Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 44 France Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 45 Rest of Europe Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 46 Rest of Europe Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 47 Rest of Europe Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 48 Rest of Europe Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 49 Asia Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 50 Asia Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 51 Asia Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 52 Asia Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 53 China Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 54 China Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 55 China Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 56 China Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 57 Japan Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 58 Japan Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 59 Japan Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 60 Japan Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 61 India Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 62 India Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 63 India Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 64 India Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 65 Australia Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 66 Australia Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 67 Australia Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 68 Australia Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 69 South Korea Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 70 South Korea Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 71 South Korea Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 72 South Korea Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 73 Latin America Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 74 Latin America Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 75 Latin America Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 76 Latin America Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 77 Brazil Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 78 Brazil Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 79 Brazil Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 80 Brazil Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 81 Mexico Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 82 Mexico Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 83 Mexico Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 84 Mexico Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 85 Rest of Latin America Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 86 Rest of Latin America Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 87 Rest of Latin America Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 88 Rest of Latin America Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 89 Middle East and Africa Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 90 Middle East and Africa Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 91 Middle East and Africa Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 92 Middle East and Africa Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 93 GCC Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 94 GCC Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 95 GCC Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 96 GCC Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 97 Africa Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 98 Africa Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 99 Africa Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 100 Africa Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)
Table 101 Rest of Middle East and Africa Hepatic Encephalopathy Therapeutics Market By Drug Class, 2021-2031, USD (Million)
Table 102 Rest of Middle East and Africa Hepatic Encephalopathy Therapeutics Market By Diagnosis, 2021-2031, USD (Million)
Table 103 Rest of Middle East and Africa Hepatic Encephalopathy Therapeutics Market By Route of Administration, 2021-2031, USD (Million)
Table 104 Rest of Middle East and Africa Hepatic Encephalopathy Therapeutics Market By Distribution Channel, 2021-2031, USD (Million)

Companies Mentioned

  • Mallinckrodt Pharmaceuticals
  • Salix Pharmaceuticals
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • ASKA Pharmaceutical Co. Ltd.
  • Bausch Health
  • Johnson & Johnson Services Inc.
  • Janssen Global Services
  • Takeda Pharmaceutical Company Limited
  • Merck & Co. Inc.

Related Topics

Related Reports

Hepatic Encephalopathy - Pipeline Insight, 2024 - Product Image

Hepatic Encephalopathy - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Overt Hepatic Encephalopathy - Pipeline Insight, 2024 - Product Image

Overt Hepatic Encephalopathy - Pipeline Insight, 2024

  • Drug Pipelines
  • 60 Pages
  • Global
From
Hepatic Encephalopathy Treatment Market Report and Forecast 2024-2032 - Product Image

Hepatic Encephalopathy Treatment Market Report and Forecast 2024-2032

  • Report
  • 180 Pages
  • Global
From
Hepatic Encephalopathy Global Market Report 2024 - Product Image

Hepatic Encephalopathy Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Hepatic Encephalopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Hepatic Encephalopathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 139 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.